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Abstract: Gaucher disease (GD) is a lysosomal storage
disorder caused by inherited deficiencies in β-glucocerebrosi-
dase (GBA). Current treatments require rapid disease diag-
nosis and a means of monitoring therapeutic efficacy, both of
which may be supported by the use of GBA-targeting activity-
based probes (ABPs). Here, we report the synthesis and
structural analysis of a range of cyclophellitol epoxide and
aziridine inhibitors and ABPs for GBA. We demonstrate their
covalent mechanism-based mode of action and uncover
binding of the new N-functionalised aziridines to the ligand
binding cleft. These inhibitors became scaffolds for the
development of ABPs; the O6-fluorescent tags of which bind
in an allosteric site at the dimer interface. Considering GBA’s
preference for O6- and N-functionalised reagents, a bi-func-
tional aziridine ABP was synthesized as a potentially more
powerful imaging agent. Whilst this ABP binds to two unique
active site clefts of GBA, no further benefit in potency was
achieved over our first generation ABPs. Nevertheless, such
ABPs should serve useful in the study of GBA in relation to
GD and inform the design of future probes.
Introduction
Gaucher disease (GD) is the most common lysosomal storage
disorder which is caused by inherited deficiencies in β-
glucocerebrosidase (glucosylceramidase, GCase, GBA, EC
3.2.1.45). This lysosomal glycoside hydrolase is encoded by the
GBA1 gene[1] and according to The Human Gene Mutation
Database (www.hgmd.org, Institute of Medical Genetics in
Cardiff[2]) over 500 genetic mutations at the GBA1 locus are
known. Moreover, mutations in the GBA1 gene have recently
been identified as the highest known genetic risk factor for
Parkinson’s disease (PD),[3–6] further intensifying therapeutic
interest in the GBA1 gene and enzyme.
GD is primarily characterized by the cellular accumulation of
glucosylceramide (GlcCer), and its deacylated derivative gluco-
sylsphingosine (GlcSph), as a result of deficient GBA activity.[7–9]
The multisystemic storage of these glycolipids leads to the
clinical symptoms of GD, which can vary considerably in
frequency and severity. Clinical manifestation of GD type 1 and
GD type 2 commonly include skeletal disease and visceral
disease affecting the spleen, kidneys, liver and heart.[10–13] In
more severe cases (GD type 3), neurological disorders also arise
due to GlcCer deposition in the brain.[14,15]
GBA is a 497 amino-acid membrane-associated glycoprotein
belonging to GH30 CAZy family (www.cazy.org) of retaining β-
glucosidases.[16] GBA is primarily responsible for catalyzing the
degradation of GlcCer by hydrolytic cleavage of the β-glucose
moiety from the aglycone to yield free ceramide and
glucose.[7,17,18] This is achieved with retention of β-anomeric
stereochemistry of the released glucose unit through a Kosh-
land double displacement mechanism using Glu340 as the
catalytic nucleophile and Glu235 as the catalytic acid-base. The
enzymatic nucleophile of GBA was identified (and corrected
from Asp443[19]) by the Wither’s lab through covalent-trapping
of the enzyme with a 2-fluoro-2-deoxy glucoside inactivator.[20]
Given the clinical importance of GBA in both GD and PD, it is
arguably the most widely studied human glucosidase, with
relentless interest in developing novel chaperones,[21–24]
inhibitors[25–27] and activity-based probes (ABPs)[28,29] to study
this enzyme in disease pathogenesis, diagnosis and treatment.
The seminal 3D structure of GBA was reported in 2003,[30]
followed by a number of co-crystal complexes with imino-sugar
inhibitors N-butyldeoxynojirimycin and N-nonyldeoxy-
nojirimycin.[31] Later studies have investigated GBA at the 3D
level to obtain insight into GD mutations and potential
molecular chaperone binding motifs.[32–35] For example, active
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site directed quinazoline modulators,[21,36] competitive 3,4,5,6-
tetra-hydroxyazepane inhibitors[37] and uncompetitive pyrrolo
[2,3-b]pyrazines inhibitors[38] have recently been reported.
Cyclophellitol, a natural product originally isolated from the
mushroom Phellinus sp.,[39] is a potent and irreversible β-
glucosidase inhibitor which exhibits considerably improved
selectivity over its close structural homologue conduritol-B-
epoxide (CBE[40,41]).[42] Building on this enhanced selectivity, and
with inspiration from the Withers’ fluoro-glycosides,[43–45] we
have developed a range of cyclophellitol-based inhibitors and
ABPs for GBA (Figure 1a,b). Indeed, tagged-cyclophellitol epox-
ides and aziridines provide a powerful activity-based protein
profiling (ABPP) approach to the study of GBA both in situ and
in vitro,[28,46] with potential applications in diagnostics and
therapeutic evaluation. In a previous study, we touched upon
the binding of a O6-adamantane substituted cyclophellitol
inhibitor and a Cy5-tagged cyclophellitol ABP for GBA,[27]
however, these structures presented just a fraction of our
structural work on the cyclophellitol-based inactivators. In fact,
most of these inhibitors and their recent ABP iterations have
not been observed on the 3D structure of GBA, hindering a
fundamental understanding of ABP reactivity, specificity and
conformation.
Here, we sought to structurally dissect the binding of
various cyclophellitol-based inhibitors and ABPs with human
GBA, comparing epoxides vs. aziridines (1, 5 vs. 2, 3, 4, 6), gluco-
vs. galacto-configuration (1, 2, 3, 5, 6 vs. 4, 7), aziridine nitrogen
functionalization (3, 6), O6-functionalisation with fluorescent
reporter groups (BODIPY 5 and Cy5 6) and bi-functionalization
at both the O6-position and aziridine nitrogen (6), (Figure 1b,c).
In doing so, we hoped to establish the binding mode of these
inactivators and uncover key mechanistic and structural
information to inform the design of more efficacious probes for
studying human GBA with regards to GD.
Results and Discussion
Tagged cyclophellitol epoxides and aziridines are valuable tools
for studying the activity of retaining glycosidases in a wide
range of applications, from biomedical purposes in human
health and disease[27,47,48] to biotechnology for the study of
Figure 1. (a) Reaction mechanism of GBA inactivation by irreversible cyclophellitol epoxide and aziridine inhibitors. Panel of (b) cyclophellitol epoxide and
aziridine inhibitors (1–4) and (c) activity-based probes (ABPs) (5–6) structurally investigated in this work. (d) Range of galacto- and gluco-configured
cyclophellitol ABPs (7–9) employed for comparative ABPP studies in this work.
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biomass degrading enzymes.[49–51] Here, we report the design,
synthesis and structural analysis of a panel of β-glucose
configured cyclophellitol-based inhibitors and ABPs on the 3D
structure of GBA with supportive ABPP studies (Figure 1).
Unsubstituted cyclophellitol epoxide (1)
A co-crystal structure of recombinant human GBA (rhGBA) in
complex with azide-tagged cyclophellitol 1 was obtained at
1.70 Å resolution, revealing classical trans-diaxial ring-opening
of the epoxide warhead to form a covalent enzyme-inhibitor
complex with the enzymatic nucleophile (Glu340), (Figure 2a).
The covalent bond length was measured to be 1.42 Å, with the
reacted cyclitol adopting the 4C1 chair conformation. This
enzyme-inhibitor complex is consistent with the β-glucoside
conformational reaction itinerary (which follows a Michaelis
Complex!Transition state�!Covalent Intermediate itinerary of
1S3!
4H3!
4C1) and is consistent with the revised conduritol-β-
epoxide (CBE) complex,[52] which was corrected from the
originally reported boat conformation.[53] Additionally, the cyclo-
phellitol moiety forms an extensive hydrogen bonding network
within the active site, making hydrogen bonds with Asp127,
Trp179, Asn234, Tyr313 and Trp381. Whilst electron density for
the C6 azido-tag was weak, likely due to flexibility and disorder,
there was sufficient density to model the azide substituent
extending ‘upwards’ into a relatively spacious cavity at the back
of the active site. An absence of azide electron density for
inhibitor 1 has been reported previously when in complex with
an unrelated bacterial β-glucoside (Thermotoga maritima,
TmGH1).[54] In contrast to this bacterial co-complex, the
improved azido-electron density of 1 in complex with rhGBA
reported here provides some insight into the conformation of
the azide-tag, which may serve as a ligation handle for two step
activity-based protein profiling (ABPP).[55,56] Indeed, further
functionalization of this azide-tag for two-step labelling is
structurally supported by the relatively large open cavity in
which the azide-substituent binds, which would likely accom-
modate larger reporter groups. However, in the case of GBA,
direct one-step ABPs have proved more effective than two-step
strategies for activity-based profiling.[56]
Unsubstituted cyclophellitol aziridine (2)
Configurationally isomeric cyclophellitol epoxides and aziridines
are often considered interchangeable, although not always
equally potent,[29,57] as inhibitors of retaining glycosidases.
Therefore, to probe whether this holds true from a mechanistic
inhibition point of view, a crystal structure rhGBA in complex
with cyclophellitol aziridine 2 was obtained at 1.70 Å resolution
to enable a detailed comparison with cyclophellitol epoxide 1.
The electron density of the resulting co-crystal structure
unambiguously shows that 2 reacts with the enzymatic
nucleophile of GBA (Glu340) through the aziridine warhead to
form a covalent trans-diaxial ring opened complex which is
essentially identical to reacted cyclophellitol epoxide 1, (Fig-
ure 2b). Indeed, 2 forms a covalent complex in the 4C1 chair
conformation with a covalent bond length of 1.46 Å to Glu340.
The only notable difference between the complex of 2 and 1
lies in their hydrogen bonding networks, where a hydrogen
bond is formed between the O6-hydroxyl of 2 and Asn396, and
the hydrogen bond to Tyr313 is lost, likely due to the
“downwards” displacement of Tyr313 in complex with 2. The
flexibility of Tyr313 has been reported previously[58] and the
“downwards” conformation observed in complex with 2
appears to preclude hydrogen bonding with the ring-opened
aziridine. Instead, the aziridine warhead forms a hydrogen bond
to a nearby water molecule in the active site. Overall, this co-
crystal structure demonstrates the almost identical binding
mode of cyclophellitol epoxides and aziridines, which supports
their interchangeable use in the development of ABPs for GBA.
Indeed, both fluorescently-tagged cyclophellitol epoxides and
aziridines have proved effective, nanomolar probes for GBA
(apparent IC50 of 1.24 nM for BODIPY-functionalized epoxide
compared to IC50 of 1.15 nM for BODIPY-functionalized
aziridine[29]), with great potential for the study of GBA in regards
to GD.
N-Acyl cyclophellitol aziridine (3)
One route to modifying cyclophellitol aziridines and facilitating
their conversion to ABPs is functionalization of the aziridine
Figure 2. Observed electron density for 1, 2 and 3 bound covalently to the catalytic nucleophile (Glu340) of rhGBA through trans-diaxial ring opening of the
epoxide or aziridine warhead. Weak electron density observed for the C6-azide tag of 1 but clear density for ring-opened N-acyl aziridine of 3. Maximum-
likelihood/σA weighted (2Fo–Fc) electron density maps contoured to 1.2 σ (a=1.30 e
 /Å3, b=1.38 e /Å3, c=1.30 e /Å3).
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nitrogen.[59] Consequently, N-acyl functionalized aziridine 3 was
synthesized and found to be a more potent inhibitor than the
unsubstituted aziridine analogue 2 (apparent IC50 of 0.07 μM for
N-acyl 3 compared to the 0.5 μM for unsubstituted 2[57]). In light
of this improved potency, we sought to investigate the
structural accommodation of the N-acyl functionalization by
GBA.
A co-crystal structure of rhGBA in complex with 3 was
obtained at 1.76 Å resolution to reveal unambiguous electron
density for the reacted cyclitol bound covalently to the
enzymatic nucleophile via trans-diaxial ring opening of the N-
acyl aziridine warhead, (Figure 2c). The cyclophellitol ring
adopts the expected 4C1 chair conformation in the resulting
complex, with a covalent bond length of 1.42 Å to Glu340. This
complex is superimposable with that formed by the unsubsti-
tuted aziridine analogue 2. Importantly, the electron density for
the N-acyl group and subsequent 2–3 carbon tail was sufficient
to model binding of the ring opened N-acyl chain to a narrow
active site cleft flanked by Tyr313 and Glu284. The carbonyl
oxygen of the N-acyl aziridine also forms a hydrogen bond with
Gln284, introducing an additional hydrogen bond to the
cyclophellitol aziridine network. It’s possible that binding of this
N-acyl moiety somewhat mimics the binding of one of the two
acyl chains of the natural GlcCer substrate, which may provide a
structural basis for the improved potency reported for N-acyl
aziridines over the unsubstituted aziridine analogue.[57,59] Fur-
thermore, N-alkyl functionalized aziridines have also proved to
be potent and selective inhibitors of GBA (apparent IC50 of
0.017 μM for N-alkyl compared to IC50 of 0.07 μM for N-acyl
[57]),
with improved chemical stability over their N-acyl
equivalents.[59] This highlights the potential for future inhibitor
and ABP development through N-acylation/alkylation of cyclo-
phellitol aziridines.
Cross-reactivity with galacto-configured aziridines
One issue surrounding ABPs is their occasional cross-reactivity
with related glycosidases. Of note, GBA can be by inhibited
both gluco- and xylo-configured substrates, with demonstrated
activity against 4-methylumbelliferyl-β-xyloside;[60] conversely,
galacto-configured cyclophellitol epoxides have proved inactive
against GBA.[61] Nevertheless, studies on other glycosidases have
shown that galacto-configured inactivators occasionally bind to
glucosidases. For example, Gloster et al., 2007 reported binding
of TmGH1 β-glucoside to galacto-hydroximolactam.[62] There-
fore, whilst we know galacto-configured cyclophellitol epoxides
do not bind GBA, we sought to assess if there is potential for
cross-reactivity with galacto-configured aziridine inhibitor 4 and
ABP 7.
Synthesis of Cy5 Tagged Galacto-Configured Cyclophellitol
Aziridine (7)
β-Galactose-configured cyclophellitol aziridine 4, prepared as
described previously,[63] was alkylated with 8-azido-1-iodooc-
tane under basic conditions (Scheme 1). Unfortunately, Cu(I)-
catalyzed azide/alkyne cycloaddition (CuAAC) with Cy5-alkyne
proved abortive and a complex mixture was obtained. In an
attempt to obtain a β-galactosidase ABP, the inverse-electron-
demand Diels-Alder (IEDDA) ligation strategy was investigated
to introduce the fluorophore at the final synthetic step. For this
purpose, norbornene-modified cyclophellitol aziridine 19 was
synthesized and reacted with tetrazine-Cy5 20 to obtain ABP 7.
The synthesis of norbornene-functionalized aziridine started
with monotritylation of 1,6-hexanediol to give 10 followed by
iodination of the primary alcohol with iodine and substitution
with sodium azide to afford 12. Reduction of azide 12 using
triphenylphosphine on beads gave amine 13. Norbornene-OSu
ester 14 was obtained according to the literature procedure[64]
as a mixture of endo- and exo-isomers. This mixture was
Scheme 1. Synthesis of ABP 7. Reagents and conditions: a) TrCl, pyridine, CH2Cl2, rt, 90 min, 95%; b) imidazole, PPh3, I2, Et2O, CH3CN, rt, overnight, 80%; c)
NaN3, DMF, 80 °C, overnight, quant; d) polymer-bound PPh3, H2O, THF, 48 h, quant; e) norbornene-OSu, DIPEA, DCE, rt, overnight, 15: 28%, 16: 68%; f) p-
toluenesulfonic acid, CH2Cl2, MeOH, rt, overnight, 86%; g) PPh3, I2, imidazole, THF, reflux, 1.5 h, 73%; h) 18, K2CO3, DMF, 75 °C, overnight, 12%; i) Cy5 tetrazine
20, MeOH, overnight, 87%.
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condensed with amine 13 resulting in a mixture of norbornene-
trityl products (exo/endo, 1 : 2.3), which were easily separated by
silica gel column chromatography. Deprotection of endo-
product 16 under acidic conditions gave alcohol 17 in 86%
yield. Treatment of 17 with triphenylphosphine, iodine and
imidazole at elevated temperatures in tetrahydrofuran. afforded
iodonorbornene 18. Cyclophellitol aziridine 7 was then N-
alkylated with iodonorbornene linker 18 using potassium
carbonate as base in DMF. Subsequent ligation[65] with Cy5
tetrazine 19 gave ABP 7 as mixture of isomers.
In-solution labelling of rhGBA by galacto-configured
cyclophellitol aziridine ABP 7
To rapidly investigate for cross-reactivity with galacto-config-
ured cyclophellitol aziridines, time-dependent labelling assays
of rhGBA with galacto-configured Cy5-tagged aziridine ABP 7
were performed (Figure 3).
To our surprise, ABP 7 (150 nM) rapidly labelled rhGBA
within 2 minutes and reached saturation within 30-minutes
(Figure 3). In comparison, labelling by gluco-configured ABP 8
(150 nM) achieved saturation within 2 minutes (Figure 3). Whilst
galacto-configured ABP 7 is slower to label rhGBA compared to
gluco-configured ABP 8, this simple labelling assay demon-
strates the cross-reactivity potential of β-galacto-configured
aziridine ABPs with GBA and suggests that such ABPs should be
carefully analysed for cross reactivity before interpretation
in vivo. However, it should also be noted that broad spectrum
ABPs have proved useful in enzyme and inhibitor discovery,
illustrating that not all ABPs need to be highly specific.[66]
Nevertheless, it is important to establish the reactivity and
binding of such ABPs to understand their limitations and
identify areas for future improvements. Therefore, cross-
reactivity data such as this are important in guiding the
selection of ABPs for a desired application.
Galacto-configured cyclophellitol aziridine (4)
To further understand the binding of galacto-configured cyclo-
phellitol aziridines with rhGBA, a co-crystal structure with
galacto-configured 4 was obtained at 1.80 Å. The resulting
complex revealed that 4 covalently modifies the catalytic
nucleophile of GBA in an almost identical fashion to gluco-
configured reagents 1 and 2. Specifically, 4 reacts with Glu340
via trans-diaxial ring opening of the aziridine trap to form a
covalent complex in the 4C1 conformation with a bond length
of 1.45 Å (Figure 4a). The key difference between this galacto-
configured complex and the gluco-configured analogues is the
axial conformation of the O4 hydroxyl, which is still able to
form a hydrogen bond with Asp127. Indeed, the hydrogen
bonding network of 4 is very similar to that of gluco-configured
1 and 2, with both O3 and O4 able to form hydrogen bonds to
Asp127 regardless of whether the sugar is gluco- or galacto-
configured. The only notable difference is the absence of a
hydrogen bond between the O4 hydroxyl and Trp381, presum-
ably owing to its axial conformation.
This led us to ponder why galacto-aziridines appear to be
reasonably potent inhibitors of GBA whereas the equivalent O6-
modified galacto-epoxides are essentially unreactive (as re-
ported by Marques et al., 2017). Overlay of galacto-aziridine 4
and gluco-epoxide 1 provides an immediate clue: the O6
hydroxyl of galacto-aziridine 4 has rotated such that it points
‘downwards’, perhaps to avoid steric clash with the axial
galacto-O4, (Figure 4b). Thus, one possible explanation for the
cross-reactivity of galacto-aziridines but not O6-substituted
galacto-epoxides, is the requirement to displace the O6-
hydroxyl for covalent binding which would not be possible
were the O6-substituted. Therefore, it appears that the place-
ment of the reporter group is important in controlling the
selectivity and cross-reactivity of cyclophellitol-based ABPs. In
combination with the ABP labelling assays of rhGBA, this co-
crystal structure serves as a caution when assuming similar
configurational specificity of cyclophellitol epoxides and azir-
idines, which evidently does not always translate to similar
glycosidase specificity.
Figure 3. Time dependent labelling of rhGBA (700 nM) by Cy5-tagged
galacto-ABP 7 (150 nM) after 2, 5, 10, 30 and 60 mins showing that labelling
reaches saturation at 30 mins. In comparison, labelling by Cy5-tagged gluco-
ABP 8 (150 nM) reaches saturation in 2mins. D=denatured protein sample
demonstrating there is no unspecific labelling with inactive rhGBA. ABP
labelled rhGBA (60 kDa) visualized by Cy5 fluorescent readout.
Figure 4. (a) Observed electron density for galacto-configured aziridine 4
bound covalently to the catalytic nucleophile (Glu340) of rhGBA through
trans-diaxial ring opening of the aziridine warhead. Maximum-likelihood/σA
weighted (2Fo–Fc) electron density map contoured to 1.2 σ (1.31 e
 /Å3) (b)
Overlay of galacto- configured aziridine 4 (teal) and gluco-configured azide-
tagged epoxide 1 (grey) demonstrating rotation of the O6 hydroxyl of 4.
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BODIPY-tagged cyclophellitol epoxide (5) in complex with
GBA inactivated with N-acyl aziridine (3)
In addition to a previously reported structure of rhGBA in
complex with the O6 Cy5 tagged cyclophellitol epoxide ABP
9,[27] a serendipitous co-complex of O6 BODIPY tagged ABP 5
and N-acyl aziridine 3 was obtained in this study by accidental
soaking of rhGBA crystals in complex N-acyl aziridine 3 with
additional ABP 5. In the resulting co-complex, clear electron
density was observed for 3 bound covalently to Glu340, with its
ring-opened N-acyl chain bound in the narrow active site cavity
flanked by Gln283 and Tyr313 (Figure 5a). Additionally, un-
ambiguous electron density for an intact molecule of ABP 5 was
observed, allowing the full ABP to be modelled at the surface of
molecule A of the crystallographic dimer, (Figure 5b). Specifi-
cally, the BODIPY tag binds at the dimer interface in a
hydrophobic cavity formed by Leu241, Tyr244, Pro245, Phe246
and Tyr313, which we reported previously to accommodate the
Cy5 tag of ABP 9.[27] The unreacted cyclophellitol of 5 sits
exposed at the surface of the protein, making no hydrogen
bonding interactions with the enzyme; however, the hydro-
phobic face of the cyclophellitol unit lies above the exposed
side chain of Leu241 (Figure 5a). Whilst the binding of ABP 5
could be considered artefactual, it is notable that very simple
torsional rotation of the linker allows the linker and cyclo-
phellitol unit to be placed in the active site, putting the epoxide
warhead in perfect super-position with the trapped aziridine
without any movement of the BODIPY group itself. In combina-
tion with the previously reported structure of rhGBA in complex
with a Cy5 tagged ABP 9,[27] this ABP 5 co-complex provides
further evidence for a unique binding mode of this hydrophobic
cavity, which has recently been exploited for the binding of a
novel class of pyrrozopyrazine activators with chaperoning
potential.[38]
GBA is notable for its tolerance, indeed preference, for O6-
substituted reagents which exhibit increased specificity for GBA
over other β-glucosidases, including non-lysosomal GBA (GBA2)
and generic GH1 β-glucosidases.[27] GBA also favours imino-
sugar inhibitors and cyclophellitol aziridines extended at the
aziridine nitrogen position. Considering these preferences and
the structural information provided by the co-complex of 3 and
5, we suggested that binding of the O6-substituent and
aziridine N-functionalization are structurally exclusive and may
reflect the enzymes specificity for a lipid substrate with two acyl
tails. This led us to ponder whether a new generation of bi-
functional aziridine ABPs, which are functionalised at the O6-
position and aziridine nitrogen, may exhibit further improve-
ments in potency and selectivity for GBA. Consequently, the
O6 Cy5 tagged N-octyl bifunctional aziridine ABP 6 was
synthesised and its GBA activity and selectivity were compared
to the parent Cy5 tagged cyclophellitol aziridine ABP 8 and
cyclophellitol epoxide ABP 9.
Cy5 Tagged Bi-Functional Cyclophellitol Aziridine (6)
Synthesis of Cy5 and N-octyl bifunctional cyclophellitol
aziridine (6)
In this work, we developed a new synthetic route towards 6-
azido octyl aziridine 27 following a key 2-napthylmethyl ether
(Nap) protecting group strategy (Scheme 2). Briefly, starting
intermediate 21 was synthesized in nine steps from d-xylose
based on chemistry developed by Madsen and co-workers.[67,68]
Benzyl deprotection was not compatible with the required
azide functionality and electrophilic aziridine, therefore, deben-
zylation of 21 with boron trichloride (BCl3) and selective
tritylation of the primary alcohol afforded intermediate 22. The
secondary alcohols were protected as Nap ethers followed by
detritylation of the primary alcohol to afford 23. Treatment of
23 with trichloroacetonitrile yielded a primary imidate inter-
mediate, which was treated with N-iodosuccinimide (NIS) to
stereospecifically afford the cyclic imidate 24. Acidolysis and
base treatment of 24 resulted in the formation of a free
aziridine, which was then alkylated with an octyl linker to form
compound 25. Tosylation of the primary alcohol of 25 followed
by azide substitution resulted in 26. Napthylmethyl ethers were
then removed by DDQ to afford compound 27, which was
Figure 5. (a) Observed electron density for binding of N-acyl aziridine 3 in
the active site of rhGBA and intact BODIPY-tagged ABP 5 at dimer interface.
Maximum-likelihood/σA weighted (2Fo–Fc) electron density map contoured
to 1.0 σ (a=1.29 e /Å3) (b) Ribbon diagram of rhGBA dimer shows binding
of ABP 5 in a hydrophobic cavity at the dimer interface (red surface), with N-
acyl 3 bound in the active site (blue surface).
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finally coupled with Cy5 using click chemistry to yield ABP 6
(Scheme 2).
Cy5-tagged bifunctional cyclophellitol aziridine (6)
To investigate the accommodation of the two functionalities of
ABP 6 by GBA, a co-crystal structure in complex with bi-
functional ABP 6 was obtained at 1.80 Å resolution, demonstrat-
ing covalent binding of the cyclophellitol aziridine to the
catalytic nucleophile of GBA (Figure 6a). Specifically, the reacted
cyclophellitol adopts the expected 4C1 chair conformation, with
a covalent bond length of 1.47 Å to Glu340. Furthermore,
unambiguous electron density for the ring opened N-alkyl
aziridine warhead was observed, allowing the first 5 carbons of
the N-octyl chain to be modelled. This was sufficient to
establish binding of the N-alkyl chain to the narrow active site
channel formed by Gln284, Tyr313, Lys346 and Trp348, which is
consistent with the complex of N-acyl aziridine 3. In fact, the N-
alkyl chain of ABP 6 extends through this pocket towards the
surface of the protein, which may provide some indication into
the binding of the fatty acid portion of the natural GlcCer
substrate which is thought to project out from the protein and
interact with the lipid bilayer.[30] Unfortunately, whilst sufficient
electron density for the O6-triazole linker and subsequent
amide group was observed, the Cy5 tag could not be modelled.
Nevertheless, the O6-triazole linker was found to bind in the
hydrophobic cavity formed by Trp348, Phe246 and Tyr313,
which we reported previously to accommodate the triazole
linker of ABP 9.[27] Additionally, this binding cavity extends
towards the broader hydrophobic allosteric site at the dimer
interface where we reported the BODIPY tag of ABP 5 to bind.
Scheme 2. Synthesis of ABP 6. Reagents and conditions: a) i) BCl3, DCM,  78 °C, 2 h; ii) TrCl, Et3N, DMAP, DMF, rt, 19 h, 30% over two steps; b) i) NapBr, NaH,
TBAI, DMF, 0 °C-rt, 5 h; ii) TsOH, DCM/MeOH (1/1), rt, overnight, 73% over two steps; c) Cl3CCN, DBU, DCM, rt, overnight; d) NIS, CHCl3, rt, 17 h, 40% over two
steps; e) i) HCl, DCM/MeOH (1/1), rt, overnight, then Amberlite IRA-67, 20 h; ii) 1-iodooctane, K2CO3, DMF, 80 °C, 16 h, 35% over two steps; f) i) TsCl, Et3N, 1-
methyl imidazole, DCM, rt, 28 h; ii) NaN3, DMF, 50 °C, 40 h, 68% over two steps; g) DDQ, DCM/H2O (10/1), rt, 24 h, 66%; h) Cy5-alkyne, CuSO4, NaAsc, DMF, rt,
overnight, 30%.
Figure 6. (a) Observed electron density for ABP 6 bound covalently to the
catalytic nucleophile (Glu340) of rhGBA by trans-diaxial ring opening of the
N-alkyl aziridine warhead. Maximum-likelihood/σA weighted (2Fo–Fc) elec-
tron density map contoured to 1.0 σ (a=1.31 e /Å3). (b) Labeling of rhGBA
(200 nM) with decreasing concentrations of ABP 6 or ABP 9 (150–0.001 nM)
at 37 °C for 30 mins followed SDS-PAGE separation. (c) Incubation of ABP 6
or ABP 9 (150 nM) with decreasing concentrations of rhGBA (500–0.01 nM)
followed by SDS-PAGE analysis. Fluorescently labelled rhGBA visualized by
Cy5 fluorescent readout. D=denatured protein sample.
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Activity-based labelling of rhGBA with ABP 6and ABP 9
Activity-based labelling of rhGBA (produced in an insect-
baculovirus expression vector system[58]) with bi-functional ABP
6 was performed and compared to labelling by its mono-
functionalized epoxide derivative ABP 9. Firstly, in solution
labelling of excess but constant rhGBA (200 nM) was performed
in the presence of decreasing ABP concentration (150–
0.001 nM), demonstrating clear concentration dependent label-
ling with a gel-detection limit of 1 nM for ABP 6 and 0.1 nM for
ABP 9 (Figure 6b). Secondly, labelling assays in which ABP 6 and
ABP 9 (150 nM) were incubated with decreasing rhGBA
concentrations (500–0.01 nM) were performed to further dem-
onstrate the concentration dependent labelling down to 1 nM
rhGBA with ABP 6 and 0.1 nM rhGBA with ABP 9, (Figure 6c).
These in gel detection limits are concordant across both assays
and demonstrate that ABP 9 exhibits ca. 10-fold increase in
potency.
In vitro activity and selectivity of Cy5 biofunctionalized
cyclophellitol aziridine ABP 6
To further investigate the potency and selectivity of ABP 6,
in vitro activity assays against GBA and two other related β- and
α-glucosidases (GBA2 and GAA) were performed and compared
to ABP 9.
ABP 6 and ABP 9 were pre-incubated with recombinant
human GBA (rhGBA, Imiglucerase), human GBA2 (from lysates
of GBA2 overexpressed cells) and recombinant human GAA
(rhGAA, Myozyme) for 3 hr followed by enzymatic activity
measurement using 4-methylumbelliferyl-β- and α-glucosides
as fluorogenic substrates. As shown in Table 1, ABP 6 proved to
be a nanomolar inhibitor of GBA (with an apparent IC50 value of
53 nM) and is inactive toward GBA2 and GAA (apparent IC50
values >100 μM), thus exhibiting comparable selective inhib-
ition of GBA (IC50 ratio >10
3 for both GBA2/GBA and GAA/GBA)
as we reported previously for ABP 9.[27]
We next investigated their labeling efficiency and selectivity
toward GBA in mouse brain lysate at pH 5.2 (containing 0.2%
taurocholate and 0.1% Triton-100) and pH 5.8 as respective
optimal conditions for GBA and GBA2 activities (Figure 7). As
expected, ABP 6 and 9 selectively labeled GBA in a concen-
tration-dependent manner under pH 5.2 (upper panels), with
significant labeling observed at 10 nM ABP. Under pH 5.8 (lower
panels), the labeling efficiency of both ABPs towards GBA
decreased and significant labeling can only be observed at
1000 nM (ABP 6) or 300 nM (ABP 9). Importantly, no labelling of
GBA2 was observed up to 1000 nM, showing good GBA
selectivity. For comparison, broad-spectrum β-glucosidase ABP
8 efficiently labelled both GBA and GBA2 at 100 nM under both
pHs.
In situ labeling of GBA and GBA2 in living cells by ABP 6, 8and
9
To further evaluate the selectivity of ABP 6, 8 and 9, in situ
labeling of GBA and GBA2 in living cells were investigated.
HEK293T cells containing endogenous GBA and overexpressed
GBA2 were treated with the ABPs at different concentrations
(1–1000 nM) for 24 hr. Cells were then washed, lysed and the
fluorescence was visualized by gel-based ABPP (Figure 8). Treat-
ment with broad spectrum ABP 8 resulted in unbiased labeling
of GBA and GBA2 at 10 nM, with labeling of both enzymes
reaching saturation at 100 nM after 24 h incubation. In compar-
ison, selective labeling of GBA in ABP 6 treated cells was
observed at 10 nM, with some GBA2 labelling observed at
higher probe concentrations (100 nM). More selective labeling
Table 1. Apparent IC50 values for in vitro inhibition of rhGBA, rhGAA and
GBA2 from overexpressed cell lysates by ABP 6 and 9. Error ranges depict
standard deviations from technical duplicates.
Compound In vitro rhGBA
IC50 (nM)
In vitro GBA2
(HEK293T lysate) IC50 (nM)
In vitro rhGAA
IC50 (nM)
ABP 6 53.1�2.65 >105 >105
ABP 9[27] 3.20�0.17 412×103�
10.1×103
>105
Figure 7. Fluorescent labeling of mouse brain lysate (25 μg total protein)
with different concentrations of bi-functional ABP 6 and mono-functional
ABP 9 at pH 5.2 (upper panels) or pH 5.8 (lower panels) after incubation for
30 min at 37 °C. Labeling by broad-spectrum β-glucosidase ABP 8 is shown
for comparison (100 nM, pH 5.2 or pH 5.8, 30 min, 37 °C).
Figure 8. In situ labeling of GBA and GBA2 in HEK293T cells with ABP 6, ABP
8 and ABP 9 at varying concentrations at 37 °C for 24 h, followed by SDS-
PAGE separation and fluorescent readout (top panel). CBB, Coomassie
Brilliant Blue staining (bottom panel).
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of GBA was achieved with ABP 9, which did not label GBA2
even at the highest concentration of probe applied (1000 nM).
Therefore, despite demonstrating that the O6- and aziridine
nitrogen substituents of ABP 6 are structurally exclusive and are
accommodated by GBA in two unique active site clefts, ABP 6
exhibits no further improvements in potency or selectivity for
GBA over the O6 mono-functionalized ABPs. Nevertheless, this
bi-functional ABP remains a nanomolar inhibitor of GBA which
provides future opportunities for ABP development through
modification of both the O6- and aziridine nitrogen substitu-
ents. This work also exemplifies the complexity of ABP develop-
ment.
Conclusion
Tagged cyclophellitols offer a powerful activity-based protein
profiling approach for the visualization and quantification of
specific enzymatic activities. Here, we report the design,
synthesis, and structural analysis of a range of cyclophellitol
epoxide and aziridine inactivators and activity-based probes
(ABPs) for human β-glucocerebrosidase (GBA). These studies
not only demonstrate the mechanism-based mode of action of
these compounds as covalent inactivators, but also highlight
binding of N-functionalized aziridines to the active site cleft.
The cyclophellitol-based inhibitors subsequently served as
scaffolds for the development of ABPs; the O6-fluorescent tags
of which bind to an allosteric site at the dimer interface. In light
of the accommodation of N-functionalized aziridines and O6-
substituents by GBA, we synthesized a bi-functional O6 Cy5 N-
octyl aziridine ABP which we hoped would offer a more
powerful imaging agent. Whilst we structurally validated that
the O6- and aziridine functionalities are structurally exclusive
and bind in two distinct active site clefts, this bi-functional ABP
showed no benefit in potency or selectivity over the mono-
functionalized ABPs. Nevertheless, this study provides funda-
mental insight into ABP reactivity, specificity, and conformation
with a tale of caution on ABP cross-reactivity when assuming
similar glycosidase specificity of configurationally isomeric
cyclophellitol epoxides and aziridines. We envisage these
inhibitors and ABPs will serve useful in the study of GBA in
relation to Gaucher Disease and inform the design of next-
generation inhibitors and probes.
Experimental Section
Synthesis: General experimental details
General synthetic details can be found in the Supporting
Information (page 3).
Experimental procedures and characterization data of
products
Inhibitors 1,[28] 2,[68] 3,[57] 4,[63] and ABPs 5[28] and 8[66] were
synthesized according to previously published procedures and their
spectroscopic data are in agreement with those reported pre-
viously. ABPs 6 and 7 were synthesised and characterised according
to the procedures outlined in the Supporting Information (pages 3–
7).
Biochemical methods: General experimental details
Recombinant human GBA (rhGBA, imiglucerase, Cerezyme®) and
GAA (rhGAA, alglucosidase alfa, Myozyme) were obtained from
Sanofi Genzyme (Cambridge, MA, USA). rhGBA was also produced
in an insect-baculovirus expression vector system (BEVS) and
purified according to previously published procedures.[58] Other
general biochemical details can be found in the Supporting
Information (page 7).
In vitro activity of ABP 6 on rhGBA, GBA2 and rhGAA
In vitro apparent IC50 measurements of ABP 6 with rhGBA and
rhGAA were determined using the fluorogenic substrate methods
described previously.[27] For in vitro apparent IC50 measurements of
GBA2, 8 volumes of cell lysates (4 μg total protein/μL) containing
overexpressed human GBA2 were firstly pre-incubated with 1 vol-
ume of MDW941 (100 nM final concentration, 0.5% (v/v DMSO)) for
30 min at 37 °C to selectively inhibit GBA activity. Lysates were then
incubated with 1 volume of ABP 6 at various concentrations for 3 h
at 37 °C, before subsequent enzymatic assay for GBA2 activity as
described earlier.[27,69] All assays were performed in duplicate sets,
each with 3 technical replicates at each inhibitor concentration.
DMSO concentration was kept at 0.5%–1% (v/v) in all assays during
incubation with compounds. In vitro apparent IC50 values were
calculated by fitting data with [inhibitor] vs. response-various slope
(four parameters) function using Graphpad Prism 7.0 software.
Average values and standard deviations were calculated from the
two sets.
Time-dependent labelling assays of rhGBA with galacto-ABP
7 and gluco-ABP 8
rhGBA produced in BEVS[58] was prepared at 700 nM in 150 mM
McIlvaine buffer pH 5.2 (containing 0.1% (v/v) Triton X-100 and
0.2% (w/v) sodium taurocholate) and ABP 7 or ABP 8 were added
to 150 nM. The reactions were incubated at 37 °C and aliquots were
taken at 2, 5, 10, 30 and 60 mins. The aliquots were immediately
denatured with Laemmli (x3) sample buffer by heating at 95 °C for
5 minutes. The samples were resolved by electrophoresis in 10%
SDS-PAGE gels, running at 200 V for ~50 minutes. Wet slab gels
were scanned on fluorescence using an AmershamTyphoon 5
Imager (GE Healthcare) with λEX 635 nm; λEM >665 nm.
Titration of ABP 6and ABP 9with rhGBA
rhGBA produced in BEVS[58] was diluted to 200 nM in 150 mM
McIlvaine buffer pH 5.2 (containing 0.1% (v/v) Triton X-100 and
0.2% (w/v) sodium taurocholate) and ABP 6 or ABP 9 were added
to 150, 100, 50, 10, 1, 0.1, 0.01 or 0.001 nM final concentration. The
reactions were incubated at 37 °C for 30 mins and denatured with
Laemmli (x3) sample buffer at 95 °C for 5 minutes. The samples
were resolved by electrophoresis in 10% SDS-PAGE gels, running at
200 V for ~50 minutes. Wet slab gels were scanned on fluorescence
using an Amersham Typhoon 5 Imager (GE Healthcare) with λEX
635 nm; λEM >665 nm.
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rhGBA Titration with ABP 6and ABP 9
rhGBA produced in BEVS[58] was prepared at 500, 250, 100, 50, 10, 1,
0.1 and 0.01 nM in 150 mM McIlvaine buffer pH 5.2 (supplemented
with 0.1% (v/v) Triton X-100 and 0.2% (w/v) sodium taurocholate).
ABP 6 or ABP 9 were added to 150 nM final concentration and the
reactions were incubated at 37 °C for 30 mins. The samples were
denatured with Laemmli (x3) sample buffer by heating at 95 °C for
5 minutes and resolved by electrophoresis in 10% SDS-PAGE gels,
running at 200 V for ~50 minutes. Wet slab gels were scanned on
fluorescence using an Amersham Typhoon 5 Imager (GE Healthcare)
with λEX 635 nm; λEM >665 nm.
Fluorescent labeling of lysates and SDS-PAGE analysis
Mouse brain lysate (25 μg total protein per sample) was diluted
with 150 mM McIlvaine buffer pH 5.2 (with 0.1% (v/v) Triton X-100
and 0.2% (w/v) sodium taurocholate) or pH 5.8 to a final 10 μL
volume and labeled with different concentrations of ABP 6 or 9
(diluted with McIlvaine buffer at matching pH to a final 5 μL
volume) at 37 °C for 30 min. Fluorescent labeling with broad-
spectrum ABP 8 was performed at 100 nM ABP concentration at
37 °C for 30 min at pH 5.2 (with 0.1% (v/v) Triton X-100 and 0.2%
(w/v) sodium taurocholate) or pH 5.8 respectively. Samples were
then denatured with 4 μL Laemmli (5x) sample buffer and heated
at 98 °C for 5 minutes. Proteins were resolved by electrophoresis in
10% SDS-PAGE gels, running at a constant of 90 V for 30 minutes
followed by 120 V for approximately 60 minutes. Wet slab gels
were scanned on fluorescence using a Typhoon FLA9500 Imager
(GE Healthcare) using λEX 635 nm; λEM >665 nm and images were
processed using ImageLab 5.2.1 (BioRad).
In situ labeling of HEK 293T cells and SDS-PAGE analysis
Labelling of HEK293T cells, containing endogenous GBA and
overexpressed GBA2, with ABPs 6, 8 and 9 was conducted based
on previously described methods[69] as outlined in the Supporting
Information (page 7).
Structural biology
Crystallisation of recombinant GBA (Imiglucerase)
Recombinant human GBA (rhGBA, Imiglucerase, Cerezyme®) sup-
plied by Sanofi-Genzyme (Cambridge, MA, USA) was dialyzed
overnight against phosphate buffered saline (PBS) (pH 7.0) and
buffer exchanged into 50 mM 2-(N-morpholino)ethanesulfonic acid
(MES), 100 mM NaCl pH 6.6 using an S75 16/600 column before
partially de-glycosylating with N-glycosidase F according to
previous procedures.[30] rhGBA was concentrated to 10 mg/mL and
crystallised by hanging drop vapor diffusion in 24-well plates using
previously reported conditions.[30]
Co-crystal complexes with imiglucerase (1, 3, 4and 5)
Co-crystal structures of Imiglucerase in complex with 1, 3, 4 and 5
were obtained either by adding a small amount of solid compound
directly to a drop containing rhGBA crystals or by adding 1 μl of the
compound dissolved in mother liquor [1.0 M (NH3)2SO4, 0.17 M
guanidine HCl, 0.02 M KCl, 0.1 M sodium acetate pH 4.6] to the
crystallisation drop and soaking for 30 minutes.
Production and crystallisation of recombinant GBA from BEVS
Recombinant human GBA (rhGBA) was produced in BEVS and
purified according to previously published procedures.[58] rhGBA
was subsequently crystallised in a 48-well MRC sitting-drop vapour-
diffusion format using previously reported 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) containing conditions.[58]
Co-crystal complexes with rhGBA from BEVS (2and 6)
Co-crystal complexes of 2 and 6 were obtained by soaking
unliganded rhGBA crystals (produced in BEVS) overnight in mother
liquor [0.2 M sodium sulfate, 0.25 M HEPES pH 7.0, 14% (v/v) PEG
3350] spiked with 0.5 mM 2 or 2 mM ABP 6 and 10% DMSO.
Data collection, structure solution and refinement
All crystals were transferred to a cryoprotectant solution containing
15% ethylene glycol or 20–25% glycerol before flash freezing in
liquid nitrogen for data collection. Data for all co-crystal complexes
were collected at the i02, i03 and i04 beamlines of the Diamond
Light Source (DLS) UK, and processed using XIA2[70] and
AIMLESS[71,72] data reduction pipeline in the CCP4i2 suite.[73] The
previous GBA PDB 2NT0[74] was used to solve the structure of
unliganded Imiglucerase by molecular replacement using
MOLREP.[75] Coordinates of unliganded Imiglucerase were used for
direct determination of the ligand complexes of 1, 3, 4 and 5 using
REFMAC.[76] Ligand complexes of 2 and 6 with rGBA (produced in
BEVS) were solved by molecular replacement using MOLREP with
the previous unliganded structure PDB 6TJK[58] as the homologous
search model.
Refinement of all structures was performed using REFMAC[76]
followed by several rounds of manual model building with
COOT.[77,78] Idealized coordinate sets and refinement dictionaries for
each ligand were generated using JLIGAND[79] or ACEDRG.[80,81]
Conformation of all sugars were validated using Privateer[82] and all
structures were validated using MolProbity[83] and the wwPDB
Validation service (validate-rcsb-1.wwpdb.org/) prior to deposition.
Data collection and refinement statistics are summarised in
Table S1 and Table S2 (Supporting Information). Crystal structure
figures were generated in CCP4 mg.[84]
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Tagged cyclophellitols offer a
powerful activity-based probe (ABP)
approach to the study of glycosidase
activities. Here, a range of cyclophelli-
tol epoxide and aziridine inhibitors
and ABPs were synthesised and inves-
tigated on the 3D structure of human
β-glucocerebrosidase (GBA), demon-
strating their mechanism-based mode
of action. We envisage these inactiva-
tors will serve useful in the study of
GBA in relation to Gaucher Disease.
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